We serve Fmoc-Oic-OH CAS:130309-37-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
| Items of Analysis | Standard of Analysis | Test Results |
| Appearance | White powder | Conform |
| Purity (HPLC) | ≥98.0% | 99.95% |
| Optical Purity | ≤0.5% D-enantiomer | ND |
| TLC | ≥98.0% | ＞98.0% |
| Melting point | 165-175℃ | 170.7-171.7℃ |
| Specific Rotation[a]20D | -38o±3o (C=1 in EtOH) | -37.6o |
| Clarity of solution | 0.3 gram in 2ml DMF clear solution | Conform |
| Water | ≤1.0% | 0.02% |
| Loss on drying | ≤1.0% | 0.37% |
| Element analysis(C、H、N) | ≤5.0% | ＜5.0% |
| Conclusion | Conforms to Factory Standard | |
Contact us for information like Fmoc-Oic-OH chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2S,3aS,7aS)-1-(((9H-Fluoren-9-yl)methoxy)carbonyl)octahydro-1H-indole-2-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Fmoc-L-Octahydroindole-2-Carboxylic Acid Use and application,Fmoc-L-Octahydroindole-2-Carboxylic Acid technical grade,usp/ep/jp grade.
Related News: It’s the first confirmed Wuhan coronavirus death from outside of mainland China, and brings the total toll to 305.Dicyclopentylphosphinmethiodid manufacturer The drug, Imfinzi, when added to chemotherapy and the drugmaker’s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.3H-Pyrazol-3-one, 1,2-dihydro-4-hydroxy-1-methyl-5-phenyl- supplier The drug, Imfinzi, when added to chemotherapy and the drugmaker’s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.9-(2-acetoxy-ethyl)-1,3-dimethyl-6,7,8,9-tetrahydro-1H-pyrimido[2,1-f]purine-2,4-dione vendor In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.The new restrictions on foreign nationals begin on February 3, Prime Minister Jacinda Ardern announced in a press release Sunday.
